Cantel Medical Corp
Most Recent
A Look at Dentsply Sirona’s Technologies Segment
Dentsply Sirona’s (XRAY) technologies segment’s sales represented ~47% of the company’s total sales in 2015.
Dexcom Tanks on Profit Booking after Directors Increase Stakes
Dexcom (DXCM) was the worst-performing stock within the iShares U.S. Medical Devices ETF (IHI) on May 26, 2016.
Profit Booking Leaves the iShares US Medical Devices ETF (IHI) in the Red
On May 19, markets declined, with the SPDR S&P 500 ETF dropping by 0.3% and the iShares US Medical Devices ETF (IHI) declining by 0.8%.
A Closer Look at IHI’s Mid-Cap Performances
Varian Medical Systems (VAR) rose by 0.4% on May 12, 2016. Varian has a weight of ~1.8% in IHI’s portfolio.
IHI Remained Flat, Hovering Around Its 52-Week High
The Markets fell silent and remained flat on April 14, 2016. The iShares US Medical Devices (IHI) closed flat with no gains and no losses for the day.
IHI: Which of Its Holdings Was the Top Performer?
In this article, we’ll analyze the YTD (year-to-date) performances of the top five holdings of the iShares US Medical Device ETF (IHI).
Cantel Medical’s Revenue and Income Rise in Fiscal 1Q16
Cantel Medical (CMN) has a market cap of $2.8 billion. Its YTD (year-to-date) price has been rising quarter-over-quarter in calendar 2015.
How Does Dentsply International Compare to Peers after 3Q15?
In this article, we’ll compare Dentsply against its peers and the ETFs that invest in Dentsply.
Nuvasive Traded above Its 100-Day Moving Average
Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.
How Does Cantel Medical Compare to Its Peers?
Cantel Medical outperformed its peers based on the net profit margin, current ratio, PE ratio, and PBV ratio. It outperformed its ETFs based on the PBV ratio.
Cantel Medical’s Revenue and Income Rose in 4Q15
Cantel Medical reported net revenue of $151.255 million in 4Q15—a rise of 6.88% compared to the net revenue of $141.508 million in 3Q15.
